Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma-Reference-Cited by-同舟云学术

Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

Published:2021-05-01 Issue:5 Volume:7 Page:744
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Patrinely J. Randall¹,Johnson Rebecca²³,Lawless Aleigha R.⁴,Bhave Prachi²⁵,Sawyers Amelia⁶,Dimitrova Maya⁷,Yeoh Hui Ling⁸,Palmeri Marisa⁹,Ye Fei¹⁰,Fan Run¹⁰,Davis Elizabeth J.¹¹,Rapisuwon Suthee¹²,Long Georgina V.²³,Haydon Andrew⁸,Osman Iman⁷,Mehnert Janice M.⁷⁹,Carlino Matteo S.⁵,Sullivan Ryan J.⁴,Menzies Alexander M.²³,Johnson Douglas B.¹¹

Affiliation:

1. School of Medicine, Vanderbilt University, Nashville, Tennessee

2. Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia

3. Mater and Royal North Shore Hospitals, Sydney, New South Wales, Australia

4. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston

5. Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia

6. Ronald O. Perelman Department of Dermatology, NYU Langone Health, New York University School of Medicine, New York, New York

7. Division of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU Langone Health, New York University School of Medicine, New York, New York

8. Department of Medical Oncology, Alfred Health, Melbourne, Victoria, Australia

9. Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick

10. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee

11. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

12. Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2777580/jamaoncology_patrinely_2021_br_210001_1621005082.0786.pdf

Reference15 articles.

1. Adjuvant pembrolizumab versus placebo in resected stage III melanoma.;Eggermont;N Engl J Med,2018

2. Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.;Patrinely;Eur J Cancer,2020

3. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.;Antonia;N Engl J Med,2018

4. Immune checkpoint inhibitor toxicity in 2018.;Johnson;JAMA,2018

5. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis.;Wang;JAMA Oncol,2018

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects;European Journal of Cancer;2024-03

2. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma;Radiotherapy and Oncology;2024-02

3. Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment;European Journal of Surgical Oncology;2024-02

4. Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy;European Journal of Cancer;2024-02

5. Exploring Advancements and Challenges in Adjuvant Melanoma Treatment;EMJ Dermatology;2024-01-30